The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-α and hepatocyte growth factor in postmenopausal women

References

• Berk B C, Weintraub W S, Alexander R W. Elevation of C-reactive protein in ‘active’ coronary artery disease. Am J Cardiol 1990; 65: 168–172
   PubMed Web of Science ®Google Scholar
• Maseri A, Biasucci L M, Liuzzo G. Inflammation in ischaemic heart disease. BMJ 1996; 312: 1049–1050
   PubMed Web of Science ®Google Scholar
• Ridker P M, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149–2153
   PubMed Web of Science ®Google Scholar
• Tamama K, Sumino H, Ichikawa S, et al. Hormone replacement therapy causes a decrease in hepatocyte growth factor in hypertensive women. J Hypertens 2003; 21: 1151–1156
   PubMed Web of Science ®Google Scholar
• Koh K K, Han S H, Shin M S, et al. Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study. Eur Heart J 2005; 26: 1362–1368
   PubMed Web of Science ®Google Scholar
• Garnero P, Jamin C, Benhamou C L, et al. Effects of tibolone and combined 17β-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial. Hum Reprod 2002; 17: 2748–2753
   PubMed Web of Science ®Google Scholar
• Bush T L, Barrett-Connor E, Cowan L D, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102–1109
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–331
   PubMed Web of Science ®Google Scholar
• Vos R M, Krebbers S F, Verhoeven C H, Delbressine L P. The in vivo human metabolism of tibolone. Drug Metab Dispos 2002; 30: 106–112
   PubMed Web of Science ®Google Scholar
• Erenus M, Ilhan H, Etler K. Effect of tibolone treatment on intima media thickness and the resistive indices of the carotid arteries. Fertil Steril 2003; 79: 268–273
   PubMed Web of Science ®Google Scholar
• Morrow D A, Ridker P M. C-reactive protein, inflammation, and coronary risk. Med Clin North Am 2000; 84: 149–161
   PubMed Web of Science ®Google Scholar
• Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997; 96: 4204–4210
   PubMed Web of Science ®Google Scholar
• Ridker P M, Buring J E, Cook N R, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391–397
   PubMed Web of Science ®Google Scholar
• Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100: 717–722
   PubMed Web of Science ®Google Scholar
• Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002; 105: 1436–1439
   PubMed Web of Science ®Google Scholar
• Stork S, von Schacky C, Angerer P. The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis 2002; 165: 301–307
   PubMed Web of Science ®Google Scholar
• Lowe G D, Upton M N, Rumley A, et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein – a cross-sectional population survey. Thromb Haemost 2001; 86: 550–556
   PubMed Web of Science ®Google Scholar
• Nakagomi A, Freedman S B, Geczy C L. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 2000; 101: 1785–1791
   PubMed Web of Science ®Google Scholar
• Prelevic G M, Kwong P, Byrne D J, et al. A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002; 77: 945–951
   PubMed Web of Science ®Google Scholar
• Acute and chronic inflammation. Robbins Pathologic Basis of Disease6th edn, R S Cotran, V Kumar, T Collins. WB Saunders, Philadelphia 1999; 50–88
   Google Scholar
• Walsh B W, Cox D A, Sashegyi A, et al. Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001; 88: 825–828
   PubMed Web of Science ®Google Scholar
• Brooks-Asplund E M, Tupper C E, Daun J M, et al. Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women. Cytokine 2002; 19: 193–200
   PubMed Web of Science ®Google Scholar
• Gohda E, Tsubouchi H, Nakayama H, et al. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest 1988; 81: 414–419
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Morishita R, Higaki J, et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens 1996; 14: 1067–1072
   PubMed Web of Science ®Google Scholar
• Dzau V J, Gibbons G H, et al. Endothelium and growth factors in vascular remodeling of hypertension. Hypertension 1991; 18(Suppl 5)III115–III121
   PubMedGoogle Scholar